Marty Burke, a professor of chemistry at the University of Illinois and co-founder of Excelsior Sciences, on making small molecule synthesis more automated for AI.

The Long Run with Luke Timmerman

Ep199: Martin Burke on Making Small Molecule Medicines for the AI Era

Abbas Kazimi, CEO of Boston-based Nimbus Therapeutics, on computation and culture for drug discovery.

Ep198: Abbas Kazimi on Computation and Culture for Drug Discovery

Viswa Colluru, founder and CEO of Boulder, Colo.-based Enveda, on drug discovery with a chemistry platform inspired by natural products.

Ep197: Viswa Colluru on Discovering Drugs Inspired by Mother Nature

Otello Stampacchia, founder and managing director of Omega Funds, on attempting to reform Europe's biotech investment climate.

Ep196: Otello Stampacchia on Europe's Biotech Crisis

Ken Song, CEO of San Diego-based Candid Therapeutics, on developing bispecific T-cell engaging antibodies for autoimmune disease.

Ep195: Ken Song on T-cell Engagers for Autoimmune Diseases

Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery by Timmerman Report

Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery

Ron Renaud, CEO of Waltham, Mass.-based Kailera Therapeutics, on developing GLP-1 based medicines to help people lose weight and live healthier lives.

Ep193: Ron Renaud on Helping People Lose Weight With GLP-1 Medicines

Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sanofi for $9.5 billion.

Ep192: Kate Haviland on Following the Science to Precision Immunology

Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD).

Ep191: Emily Conley on Small Molecules to Correct a Rare Kidney Disease

Neil Kumar is founder and CEO of Palo Alto, Calif.-based BridgeBio Pharma, a rare disease drug developer.

Ep190: Neil Kumar on Building a Rare Disease Drug Company

Vetenskap

"The Long Run"

Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous. 

Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.

Ep199: Martin Burke on Making Small Molecule Medicines for the AI Era

The Long Run with Luke Timmerman

Fler avsnitt från "The Long Run with Luke Timmerman"